Abstract:Abstract An established tumor is a complex tissue composed of tumor cells, stromal cells, inflammatory cells, vasculatures, and extracellular matrices, all of which are defined together as the tumor microenvironment. Successful tumor control by immunotherapy requires activation of the immune system, expansion of the effector cells, infiltration of activated effector cells to the tumor tissue, and destruction of the tumor cells. Our previous studies have showed that anti-tumor effect of current tumor immunotherapies, such as checkpoint blockade, relies on a significant number of spontaneous tumor infiltrating lymphocytes. However, established tumors often inhibit peripheral lymphocytes entering tumor tissues for tumor destruction. Inflammatory mediators, especially cytokines, chemokines, and adhesion molecules, play important roles in the recruitment and activation of various types of innate and adaptive immune cells. As a proof-of-concept study, we targeted tumor tissues with LIGHT, a member of the tumor necrosis factor super family. Our data suggested that targeting tumor with LIGHT is able to induce the production of several cytokines/chemokines, which recruit T cells into tumor microenvironment, leading to tumor regression. Furthermore, combination therapy with LIGHT is able to overcome tumor resistance to checkpoint blockade. Thus, these data suggested that manipulating tumor microenvironment with cytokines/chemokines that are able to recruit effector cells represents a promising strategy for tumor immunotherapy. To better understand the role of individual cytokine/chemokine, we utilized chemokine array to systemically analyze tumor microenvironments. By comparing chemokine profiles from immunotherapy-sensitive and -insensitive tumors, we found a significant difference which might be responsible for their sensitivity to immunotherapies. Sensitive tumor is characterized with a higher level of chemokines associated with lymphoid cell trafficking, such as CXCL9 and CCL22. In contrast, insensitive tumor is characterized by a higher levels of chemokines associated with myeloid cell, such as MCP-1 and CCL11. The contributions and their therapeutic potentials of these cytokines/chemokines will be studied in the next step. Citation Format: Haidong Tang, Xiangyan Qiu, Yang Wang, Yang-Xin Fu. Manipulating tumor microenvironment for immunotherapy [abstract]. In: Proceedings of the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; 2016 Sept 25-28; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2016;4(11 Suppl):Abstract nr A112.

Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade

Creating a T cell-inflamed tumor microenvironment overcomes resistance to checkpoint blockade

Abstract A088: Increase Lymphocyte Infiltration Overcomes Tumor Resistance to Checkpoint Blockade

Targeting IFNα to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance

LIGHT/TNFSF14 promotes CAR-T cell trafficking and cytotoxicity through reversing immunosuppressive tumor microenvironment

Shining a LIGHT on myeloid cell targeted immunotherapy

Targeting tumors with LIGHT to generate metastasis-clearing immunity.

Priming of Naive T Cells Inside Tumors Leads to Eradication of Established Tumors

Abstract A112: Manipulating Tumor Microenvironment for Immunotherapy

LIGHT enhanced bispecific antibody armed T-cells to treat immunotherapy resistant colon cancer

Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1

Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s

Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer

Immunotherapy Goes Local: The Central Role of Lymph Nodes in Driving Tumor Infiltration and Efficacy

Targeting type I interferon tumor entry by anti-PD-L1 creates feedforward antitumor responses to overcome innate and adaptive resistance

Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Pheophorbide A–Mediated Photodynamic Therapy Potentiates Checkpoint Blockade Therapy of Tumor with Low PD–L1 Expression

Resistance mechanisms of immune checkpoint inhibition in lymphoma: Focusing on the tumor microenvironment

Enhancing Anti-PD-1/PD-L1 Immune Checkpoint Inhibitory Cancer Therapy by CD276-Targeted Photodynamic Ablation of Tumor Cells and Tumor Vasculature

Modulation of T-cell-mediated Immunity in Tumor and Graft-Versus-host Disease Models Through the LIGHT Co-Stimulatory Pathway.